Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 17

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 3
Chunk 17
---
──────────────────────────────────────

  the cost of clinical trials of any product candidates that we may identify and pursue being greater than we anticipate;  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  clinical trials of any product candidates that we may identify and pursue producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct ad...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  transfer of manufacturing processes to larger-scale facilities operated by a Contract Manufacturing Organization, or CMO and delays or failures by our CMOs or us to make any necessary changes t...  

  delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of product candidates that we may identify for use in clinical trials or the inabilit...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Any inability to successfully initiate or complete
clinical trials could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing
or formulation changes to our product candidates, we may be required to, or we may elect to, conduct additional preclinical studies or
clinical trials to bridge data obtained from the modified product candidates to data obtained from preclinical and clinical research conducted
using earlier versions. Clinical trial delays could also shorten any periods during which our products have patent protection and may
allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize product candidates
and may harm our business and results of operations.

In addition, any disruptions that may be caused
by any resurgence of the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling,
conducting or completing future clinical trials. We could also encounter delays if a clinical trial is suspended or terminated by us,
by the data safety monitoring board, or DSMB, or by the FDA, the EMA or other comparable foreign regulatory authorities, or if the IRBs
of the institutions in which such trials are being conducted suspend or terminate the participation of their clinical investigators and
sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure
to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of